Samil Pharmaceutical Co.,Ltd

KSE 000520.KS

Samil Pharmaceutical Co.,Ltd Shareholders' Equity for the year ending December 31, 2023: USD 98.17 M

Samil Pharmaceutical Co.,Ltd Shareholders' Equity is USD 98.17 M for the year ending December 31, 2023, a -1.23% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Samil Pharmaceutical Co.,Ltd Shareholders' Equity for the year ending December 31, 2022 was USD 99.40 M, a 80.62% change year over year.
Samil Pharmaceutical Co.,Ltd Shareholders' Equity for the year ending December 31, 2021 was USD 55.03 M, a -5.67% change year over year.
Samil Pharmaceutical Co.,Ltd Shareholders' Equity for the year ending December 31, 2020 was USD 58.34 M, a 8.68% change year over year.
Samil Pharmaceutical Co.,Ltd Shareholders' Equity for the year ending December 31, 2019 was USD 53.68 M, a 7.06% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

KSE: 000520.KS

Samil Pharmaceutical Co.,Ltd

CEO	Mr. Kang Huh
IPO Date	Jan. 4, 2000
Location	South Korea
Headquarters	155 Hyoryeong-Ro
Employees	586
Sector	Healthcare
Industries Pharmaceuticals Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care

Description

Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of indispensable medicines in South Korea. It offers hepatic, gastrointestinal, vasodilator, antithrombotic, respiratory, skeletal muscle relaxants, circulatory, neurological, antibiotics, metabolic, antihistamines, immunosuppressive, hormone, anti-tumor, urinary, and ophthalmic drugs, as well as antipyretic, analgesic, and anti-inflammatory agents. The company also provides OTC products and sanitary aids. Samil Pharmaceutical Co.,Ltd was founded in 1947 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years